Evidence map›Paper›PMID 39705501›Full record

ArticleAmerican journal of clinical pathology2025

Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.

Katherine B Case, Dylan J Martini, Melad N Dababneh, Samuel Bidot, Bassel Nazha, Jacqueline Brown, Shreyas Joshi, Vikram Narayan, Vaunita Parihar, Faisal Saeed and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of clinical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Katherine B CaseEmory University School of Medicine, Atlanta, GA, US.
Dylan J MartiniDepartment of Internal Medicine, Massachusetts General Hospital, Boston, MA, US.
Melad N DababnehDepartment of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, AL, US.
Samuel BidotDepartment of Pathology, Massachusetts General Hospital, Boston, MA, US.
Bassel NazhaDepartment of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA, US.ORCID 0000-0001-6385-1329
Jacqueline BrownDepartment of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA, US.
Shreyas JoshiWinship Cancer Institute of Emory University, Atlanta, GA, US.
Vikram NarayanWinship Cancer Institute of Emory University, Atlanta, GA, US.
Vaunita PariharWinship Cancer Institute of Emory University, Atlanta, GA, US.
Faisal SaeedWinship Cancer Institute of Emory University, Atlanta, GA, US.
Mehmet Asim BilenDepartment of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA, US.
Lara R HarikWinship Cancer Institute of Emory University, Atlanta, GA, US.

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Ragini Reiney Kudchadkar · 2009 to 2026
$47.5M
NCINCI NIH HHS P30 CA138292NIH HHS P30CA138292
6 · The paper itself

Abstract

objectivesUrothelial carcinomas (UCs) encompass a heterogeneous group of tumors. Several histopathologic features are associated with poor clinical outcomes and limited treatment options. With new rising therapeutic modalities, we aimed to determine the pattern of expression of Trop-2 and ephrin B2 in UC with aggressive subtype histology and/or divergent differentiation (SH/DD).

methodsWe performed a retrospective analysis of 113 UC samples with SH/DD at our institution from 2011 to 2021. Immunohistochemical staining for Trop-2 and ephrin B2 expression was performed on all cases. Expression was determined by the percentage of samples with a moderate or strong H-score.

resultsOur results show Trop-2 expression was the highest in squamous cell carcinoma and UC with squamous differentiation, adenocarcinoma and UC with glandular differentiation, and plasmacytoid subtype, while ephrin B2 expression was highest in adenocarcinoma, UC with glandular differentiation, and small cell carcinoma.

conclusionsExpression of Trop-2 and ephrin B2 may demonstrate therapeutic possibilities for patients with SH/DD, who usually have limited treatment options, particularly in small cell carcinoma, in which few targets have been identified. Clinical trials to investigate the efficacy of these novel treatments are warranted.

Indexed as

Antigens, NeoplasmBiomarkers, TumorCarcinoma, Transitional CellCell Adhesion MoleculesEphrin-B2Urinary Bladder NeoplasmsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Squamous CellCell DifferentiationFemaleHumansImmunohistochemistryMaleAntigens, NeoplasmBiomarkers, TumorCell Adhesion MoleculesEphrin-B2TACSTD2 protein, humanadenocarcinomaantibody drug conjugatebladdercarcinomadivergentephrin B2glandularsmall cell carcinomasquamoussubtypetargetedtherapyTrop-2urothelialvariant

Identifiers

PMID39705501
PMCPMC12009667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.